Plasma glycoprotein V levels in the general population: Normal distribution, associated parameters and implications for clinical studies

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH06-06-0296
Issue:2006: 96/4 (Oct) pp. 391-543
Pages:505-511

Plasma glycoprotein V levels in the general population: Normal distribution, associated parameters and implications for clinical studies

Boris Aleil1,2,3, Nicolas Meyer4, Valérie Wolff1, Daniel Kientz1, Marie-Louise Wiesel1, Christian Gachet1,2,3, Jean-Pierre Cazenave1,2,3, François Lanza2,3
1EFS-Alsace, Strasbourg, France; 2Inserm, U311, Strasbourg, France; 3Université Louis Pasteur, Strasbourg, France; 4Département de Santé Publique, Unité de Méthodologie et Biostatistique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Summary

Soluble glycoproteinV (sGPV) is a new plasma marker of thrombosis released from the platelet surface by thrombin. sGPV levels are increased in patients with atherothrombotic diseases, but the determinants of sGPV levels are unknown in the general population. Identification of these potential confounding factors is needed for correct design and analysis of clinical studies on cardiovascular diseases.The aim of this study was to determine the normal range of plasma values and the factors controlling sGPV levels in a population of normal individuals.Three hundred blood donors were recruited at the Etablissement Français du Sang-Alsace for the measurement of plasma levels of sGPV, platelet factor 4 (PF4), thrombin-antithrombin complexes (TAT) and D-dimers.The plasma level of sGPV was (median [interquartile range]) 27.5 [23.5–34.4] μg/l and displayed a Gaussian distribution. sGPV had a lower interindividual coefficient of variation (33%) than PF4 (176%), TAT (87%) or D-dimers (82%). sGPV levels were independent of age and sex but sensitive to red cell (r=0.412; p<0.0001) and platelet counts (r=0.267; p=0.001), total cholesterol (r=−0.313; p<0.0001), food intake (r=0.184; p=0.0014) and smoking (r=−0.154; p=0.039). Contrary to PF4 and TAT, sGPV did not differ between venous and arterial blood samples of 12 healthy individuals. Red cell and platelet counts, total cholesterol, current smoking and recent food intake are important determinants of sGPV levels and must be taken into account in clinical studies using sGPV as a thrombosis marker. Normal distribution of sGPV levels in the general population supports its use in clinical applications.

Keywords

Platelet, Glycoprotein V, GPV, thrombosis marker

DOI

http://dx.doi.org/10.1160/TH06-06-0296

You may also be interested in...

1.

Marie-Christine Alessi, Irène Juhan-Vague

Thrombosis and Haemostasis 2008 99 6: 995-1000

http://dx.doi.org/10.1160/TH07-11-0682

2.

Charalambos Tymvios1, Sarah Jones1, Christopher Moore1, Simon C. Pitchford1, Clive P. Page2, Michael Emerson1

Thrombosis and Haemostasis 2008 99 2: 435-440

http://dx.doi.org/10.1160/TH07-07-0479

3.

Akifumi Inomo*, Toshitaka Sugi*, Yoshimi Fujita, Hidehiko Matsubayashi, Shun-ichiro Izumi, Mikio Mikami

Thrombosis and Haemostasis 2008 99 2: 316-323

http://dx.doi.org/10.1160/TH07-07-0447



Articles

You've 490 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...